Friday, 22 Jun 2018

You are here

Hip Replacement Augments Longevity

Data from Swedish hip replacement registry finds that total hip arthroplasty (THA) not only improves quality of life, it is also associated with increased life expectancy that lasts at least 0 years after surgery, especially in primary osteoarthritis (OA) patients. (Citation source: https://buff.ly/2CQW0cC)

Researchers studied the survival rate of 131,808 patients undergoing THA from 1999-2012.  There were 21,755 deaths (16.5%) with a median follow-up of 5.6 years.

After one year, survival was one percent better in THA patients and 3% by five years. By 12 years, survival was no longer different for THA patients compared to the general population.

The survival difference was significant mainly among patients diagnosed with primary osteoarthritis.

Increasing comorbidities, lower education and being single led to lower survival after THA. Poorer relative survival was seen with THA done for osteonecrosis of the femoral head, inflammatory arthritis and secondary osteoarthritis. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.

Restless Sleep and Inactivity Intertwined in OA

Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Bisphosphonate Drug Holidays May Result in Fractures

A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures.  (Citation source: http://bit.ly/2FHbFwp)

USPSTF Recommendations on Vitamin D, Calcium Supplementation to Prevent Fractures

The U.S. Preventive Services Task Force (USPSTF) concludes current scientific evidence is insufficient regarding the use of vitamin D and calcium, alone or in combination, to prevent fractures in men and premenopausal women. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women. Current scientific evidence is insufficient regarding the use of vitamin D and calcium at doses greater than 400 IU of vitamin D and greater than 1,000 mg of calcium in postmenopausal women.